TOYOPEARL GigaCap DEAE - PUSHING THE PRODUCTIVITY OF ANION EXCHANGE STEPS - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

TOYOPEARL GigaCap DEAE - PUSHING THE PRODUCTIVITY OF ANION EXCHANGE STEPS


TOYOPEARL GigaCap DEAE - PUSHING THE PRODUCTIVITY OF ANION EXCHANGE STEPS

Tosoh Bioscience is introducing a new weak anion exchanger that offers a very high dynamic binding capacity while maintaining good peak resolution. Besides other applications this is of special interest for the purification of plasma proteins.

TOYOPEARL GigaCap DEAE-650 is the newest member of the renowned TOYOPEARL GigaCap series of high capacity ion exchange media. The polymeric base bead was chemically modified to provide a high number of anionic binding sites for increased resin capacity. The typical dynamic binding capacity (DBC) of over 150 g/L for bovine serum albumin exceeds the DBC of all other commercial available DEAE chromatography media. The resin was proved to be stable for more than 100 cleaning-in-place (CIP) cycles with 0.5 M NaOH. Good mass transfer kinetics enable the resin to maintain DBC at faster linear velocities and leads to a narrow elution peak. This results in smaller and more concentrated in-process pool volumes, thus reducing the amount of water and buffer needed. The high capacity and low back pressure creates opportunities for increased throughput in various anion exchange purification steps and is ideally suited for efficient plasma protein purification.

Contact:

TOSOH BIOSCIENCE GmbH
Zettachring 6 70567 Stuttgart, Germany
Tel. +49 (0)711 13257-0
Fax: +49 (0)711 13257-89

sales-marketing.tbg@tosoh.com

www.separations.eu.tosohbioscience.com/Products/ProcessMedia/ByMode/IEC/ToyopearlGigaCapDEAE-650M.htm

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here